We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00 Could […]
touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022. Questions What are the hopes of the new drug delivery mechanism using L-asparaginase to treat […]
Over the past two decades, gemcitabine has been the first-choice adjuvant therapy for advanced pancreatic cancer.1 Recent trial findings have evolved first-line standard of care; longer survival times and higher response rates have been achieved with combination treatments, compared with gemcitabine alone.1–3 The MPACT trial demonstrated survival benefits with nab-paclitaxol plus gemcitabine over gemcitabine alone […]
We joined Michel Ducreux at ESMO 2019 to discuss the challenges and recent advances in treating pancreatic cancer. Questions 1. What are the major challenges in the treatment of advanced pancreatic cancer? (00:04) 2. Why is it important to treat advanced pancreatic cancer faster? (00:30) 3. What have been the most important recent clinical advances […]
Pancreatic cancer is one of the most difficult cancers to treat, and is still considered incurable. The one-year relative survival rate is 20% and the five-year survival rate is 9%, the lowest of any solid tumour.1 These low rates reflect the fact that more than 80% of tumours have spread beyond the pancreas at the […]
Insights into CCBs and pancreatic cancer presented at American Association for Cancer Research Annual Meeting, Chicago, IL, US, April 14–18, 2018. Pancreatic cancer will be responsible for approximately 44,330 deaths in 2018 in the US, according to the American Cancer Society (ACS).1 It is one of the most feared malignancies because of its dismal prognosis; […]
Get the latest clinical insights from touchONCOLOGY